Other Consolidated Financial Statement Detail

Other Income (Expense), Net

Components of other income (expense), net, are summarized as follows:



	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In millions)	2017			2016			2017			2016
Interest income	$	20.6		$	16.4		$	54.2		$	43.0
Interest expense	(61.8		)	(66.0		)	(188.8		)	(195.2		)
Gain (loss) on investments, net	(4.0		)	0.8			(15.0		)	(0.3		)
Foreign exchange gains (losses), net	6.7			(4.9		)	8.4			(2.6		)
Other, net	(5.1		)	(4.4		)	(8.2		)	(14.3		)
Total other income (expense), net	$	(43.6	)	$	(58.1	)	$	(149.4	)	$	(169.4	)

Other Current Assets

Other current assets include prepaid taxes totaling approximately $714.4 million and $817.0 million as of September 30, 2017 and December 31, 2016, respectively.

Accrued Expenses and Other

Accrued expenses and other consists of the following:



(In millions)	As of September 30, 2017		As of December 31, 2016
Current portion of contingent consideration obligations and milestones	$	611.5	$	580.8
Revenue-related reserves for discounts and allowances	467.2		438.6
Employee compensation and benefits	241.9		282.9
Collaboration expenses	180.1		130.9
Royalties and licensing fees	190.8		195.8
Construction in progress	157.6		134.0
Accrued TECFIDERA litigation settlement and license charges	—		454.8
Other	606.1		685.7
Total accrued expenses and other	$	2,455.2	$	2,903.5

Pricing of TYSABRI in Italy - AIFA

In the first quarter of 2017, we reached an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods. As a result, in the first quarter of 2017 we recognized EUR41.8 million (approximately $45.0 million) in revenues for sales which were previously deferred. These amounts were previously accrued for and included in the table above in Other as of December 31, 2016.

For additional information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 20, Litigation, to our consolidated financial statements included in our 2016 Form 10-K.